SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, has unveiled new data on a ...

Gardening/yardwork is one of the few forms of leisure physical activity that people tend to do more as they age.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Topline phase 3 results show retatrutide led to meaningful weight reduction and pain relief in adults with overweight or obesity and knee OA.

Eli Lilly drug candidate retatrutide achieved up to 28.7% weight loss and reduced knee osteoarthritis pain in a phase 3 trial of 445 adults.

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 ...

Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with ...

Nov. 19, 2025 — If knee arthritis were a growth stock, you’d want to own a few shares. Fifty percent of adults in the U.S. will develop knee osteoarthritis, which happens when the cartilage in the ...

Hip and knee pain often stems from arthritis, a condition affecting joints. Understanding its causes, like aging or autoimmune diseases, is key. Symptoms include persistent pain, stiffness, and ...

Nearly 20% of Americans 45 and older have knee osteoarthritis. Worldwide, the number is predicted to increase nearly 75% by 2050, because of aging, population growth and obesity. Knee osteoarthritis ...